Panelists discuss how atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and recurring ...

More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...

The challenges veterinary professionals and clients face when dealing with a patient with allergic dermatitis, and what ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.